Direct oral anticoagulants reduce cancer-associated venous t
Researchers assessed the safety and efficacy of various DOACs among 2,894 patients with cancer-associated VTE included in four randomized controlled trials.

Results showed use of DOACs significantly decreased recurrent VTE events compared with dalteparin (Fragmin, Pfizer; OR = 0.59; 95% CI, 0.41-0.86) while not significantly increasing major bleeding events (OR = 1.34; 95% CI, 0.83-2.18).

Mixed treatment comparisons revealed apixaban (OR = 0.41; 95% CI, 0.16-0.95) and rivaroxaban (OR = 0.58; 95% CI, 0.37-0.9) significantly decreased recurrence of VTE events compared with dalteparin. However, edoxaban significantly increased major bleeding compared with dalteparin (OR = 1.73; 95% CI, 1.04-3.16) and rivaroxaban significantly increased clinically relevant nonmajor bleeding compared with dalteparin and other DOACs. No differences between DOACs regarding VTE recurrence and major bleeds.

Direct oral anticoagulants significantly reduced risk for recurrence of cancer-associated venous thromboembolism compared with dalteparin among patients with cancer.